Please use a PC Browser to access Register-Tadawul
Is Stronger Net Interest Income And Lower Charge-offs Altering The Investment Case For Zions (ZION)?
Zions Bancorporation NA ZION | 62.50 | +1.66% |
- Zions Bancorporation, National Association reported past fourth-quarter 2025 results with net interest income rising to US$683 million and net income to US$263 million, lifting diluted earnings per share from continuing operations to US$1.76 from US$1.34 a year earlier.
- For 2025 as a whole, the bank grew net interest income to US$2.63 billion and net income to US$899 million, while sharply reducing quarterly net charge-offs to US$7 million from US$36 million, supporting management’s message of improving credit quality and operating efficiency.
- Against this backdrop, we’ll examine how stronger net interest income shapes Zions Bancorporation’s investment narrative for investors assessing its regional banking role.
Uncover the next big thing with financially sound penny stocks that balance risk and reward.
What Is Zions Bancorporation National Association's Investment Narrative?
To own Zions Bancorporation, you have to believe in a fairly traditional regional banking story: steady net interest income, disciplined credit costs and a management team focused on efficiency and shareholder returns. The latest quarter reinforces that picture, with net interest income, earnings and EPS all higher while quarterly net charge-offs fell to US$7 million from US$36 million. That improvement in credit quality and profitability could strengthen near term catalysts such as potential capital returns, especially with management now talking more openly about buybacks later in the year. At the same time, the share price still trades on a lower earnings multiple than many peers, even after a solid 90‑day move, suggesting the earnings beat has not radically altered the market’s risk view. The key risk remains that credit conditions or funding costs turn less friendly just as that capital return story gains momentum.
However, one risk in particular is worth understanding in more detail before making up your mind. Despite retreating, Zions Bancorporation National Association's shares might still be trading above their fair value and there could be some more downside. Discover how much.Exploring Other Perspectives
Explore 3 other fair value estimates on Zions Bancorporation National Association - why the stock might be worth just $66.05!
Build Your Own Zions Bancorporation National Association Narrative
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your Zions Bancorporation National Association research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Zions Bancorporation National Association research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zions Bancorporation National Association's overall financial health at a glance.
Looking For Alternative Opportunities?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.
- These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.


